ISPOR 6TH
LATIN AMERICA
CONFERENCE
15-17 September 2017 / Hotel Transamérica São Paulo / São Paulo, Brazil

Driving Better Health Outcomes
Through Stakeholder Engagement

Program and Schedule of Events

www.ispor.org

#ISPORsaoPaulo
ISPOR MEETING APP: SEE PAGE 24
WI-FI NETWORK: HTWireless
PASSWORD: ispor2017
MENTAL HEALTH - Cost Studies

PMH6 14 ANÁLISE DE CUSTO-COMPARAÇÃO ENTRE OS PROGRAMAS PARA PESSOAS COM DEFICIÊNCIA INTELECTUAL E DO DESENVOLVIMENTO COGNITIVO: SUPORTE INDIVIDUALIZADO E INSTITUIÇÕES DE SAÚDE MENTAL.
Ramos e Daciel G. University of Colorado, Denver, CO, USA.

PMH7 15 RESOURCE ALLOCATION FOR TREATING ALCOHOL AND DRUG MISUSE IN PSYCHOSOCIAL CARE CENTER IN BRAZIL: IS CURRENT NATIONAL FUNDING ENOUGH FOR COVERING ITS TOTAL COSTS?
Bertani P, Razzovek D. Universidade Federal de São Paulo, São Paulo, Brazil.

PMH8 16 ESTIMATION OF THE COST OF RELAPSE IN SCHIZOPHRENIA: A COMPARISON BETWEEN COLOMBIA, PANAMA AND MEXICO
Guimarães Corbi L1, Aquilino A2, Suppini V2, Aguílone A2, Guerrero E3, Arias J4, Janssen Mexico, Mexico City, Mexico; Janssen-Cilag SA, Bogota, Colombia; Janssen Central America and the Caribbean, Panama, Panama; Janssen-Cilag Farmacêutica Ltda, Sao Paulo, Brazil.

PMH9 17 THE IMPACT OF LONG ACTING INJECTABLE ANTIPSYCHOTICS ON THE HEALTH AND ECONOMIC OUTCOMES OF SCHIZOPHRENIA PATIENTS IN BRAZIL
Ferreira SA1, Arias J1, Keenan A1, Zheng Y1, Janssen-Cilag Farmacêutica Ltda, São Paulo, Brazil; Janssen-Cilag Latin America, Panama city, Panama; Janssen R&D US, Rantian, NJ, USA.

PMH10 18 AVALIAÇÃO DOS CUSTOS POR TIPO DE INTERNAÇÃO EM UMA OPERADORA DE PLANOS DE SAÚDE: UMA ANÁLISE DE DADOS DO MUNDO REAL

PMH11 10 ECONOMIC EVALUATION OF AYAHUASCA TREATMENT FOR SUBSTANCE USE DISORDER (SUD) PATIENTS IN A PERUVIAN CENTRE.
Tribuzi I, Petit Rl, Mendive F, Palla I, Turchetti O1, Sotucu Sao Norte de Portugal, Pisa, Italy; Takawasi Center, Tarapoto, Peru.

MENTAL HEALTH - Health Care Use & Policy Studies

PMH13 10 COMMUNITY PHARMACISTS’ INTEREST IN AND ATTITUDE TO PHARMACY PRACTICE RESEARCH IN ETHIOPIA: A CROSS-SECTIONAL STUDY
Shiferaw Atsede AS1, Gebreab Yohannes EA1, Gebreab Abasse BM1, Erku DA2, University of Gonder-College of Medicine and Health Sciences, Gonder, Ethiopia; 2University of Gonder, Gonder, Ethiopia.

NEUROLOGICAL DISORDERS - Clinical Outcomes Studies

PND1 11 OSTEOPATHIC MANIPULATIVE THERAPY IN PATIENTS WITH HEADACHE: SYSTEMATIC LITERATURE REVIEW
Vasconcellos JP1, Vassconcellos Bc2, Fernandes RA1, Sense Company, Rio de Janeiro, Brazil; 2CETRO Reabilitação, Rio de Janeiro, Brazil.

PND2 12 EFFECTIVENESS OF LACOSAMIDE FOR THE TREATMENT OF NON-CONTROLLED FOCAL EPILEPSY
Monita ME1, Phuklukka EM1, Soares E1, Cendes P1, Yasuda CL1, Evangelista-Fodor 2, Boscopi MR1, Reginato GB1, Hospital São Lucas, Brazil; 2Hospital São Lucas, Brazil; 3Faculdade of Medical Sciences of State University of Campinas, Campinas, Brazil; 4Faculty of Medical Sciences, State University of Campinas, Campinas, Brazil; 5Sotucu Medical School of the Universidade Estadual Paulista – UNESP, Botucatu, Brazil.

PND3 13 EVALUACIÓN DE EFECTIVIDAD Y SEGURO DE LA TERAPIA FARMACOLÓGICA PARA EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON INICIAL Y AVANZADA EN COLOMBIA.
Contreras J, Castro P, Sierra J, Orzoco L. Universidad de Antioquia, Medellin, Colombia.

NEUROLOGICAL DISORDERS - Cost Studies

PND4 14 ANÁLISE DE CUSTO EFETIVIDADE DA TOXINA ONABOTULINICA A NO TRATAMENTO PREVENTIVO DA MIGRÂNEA CRÓNICA
Caddeo A, Pepe C, Asano E, Romariz G, Allergan, Sao Paulo, Brazil; 2Sense Company, Sao Paulo, Brazil.
RESOURCE ALLOCATION FOR TREATING ALCOHOL AND DRUG MISUSE IN MEXICO: A SYSTEMATIC REVIEW OF INTERNATIONAL NATIONAL FUNDING ENOUGH FOR COVERING ITS TOTAL COSTS?

María José Yañez,

University of Guadalajara

ABSTRACT

This paper evaluates the costs of treating alcohol and drug misuse in Mexico. The study identified 40 peer-reviewed articles in PubMed, Psychinfo, Socio-index, PsycARTICLES, and other sources. The costs of treatment were calculated using a cost analysis approach, considering direct and indirect costs. The total cost of treatment for alcohol and drug misuse in Mexico was estimated to be $10.2 billion per year. The study found that current funding is not enough to cover the total costs of treatment. The study recommends increasing funding for treatment programs to ensure that everyone in need of treatment receives it.

OBJECTIVES: The objectives of this study were to: 1) evaluate the costs of treating alcohol and drug misuse in Mexico, 2) identify the sources of funding, and 3) recommend strategies to increase funding for treatment programs.

METHODS: A systematic review of peer-reviewed articles was conducted using PubMed, Psychinfo, Socio-index, PsycARTICLES, and other sources. The costs of treatment were calculated using a cost analysis approach, considering direct and indirect costs.

RESULTS: The total cost of treatment for alcohol and drug misuse in Mexico was estimated to be $10.2 billion per year. The study found that current funding is not enough to cover the total costs of treatment.

CONCLUSIONS: The study recommends increasing funding for treatment programs to ensure that everyone in need of treatment receives it.